innerbuddies gut microbiome testing

Gut Microbiome & Psoriasis: The Gut–Skin Link in Psoriatic Disease

Psoriasis isn’t only a skin condition—it’s a whole-body inflammatory disorder, and emerging research points to the gut microbiome as a key player. The communities of bacteria (and their metabolites) living in your intestines can influence immune signaling throughout the body, potentially shaping the inflammation that drives psoriasis and related psoriatic disease.

In studies of psoriatic disease overlap, researchers have observed differences in gut microbial composition and function, alongside changes in gut barrier integrity. When the intestinal lining becomes more permeable (“leaky gut” is the simplified concept), microbial products can interact with the immune system, helping activate pro-inflammatory pathways involved in psoriasis—particularly the IL‑23/Th17 axis. This connection may help explain why some people experience flares that track with diet changes, stress, infections, antibiotic exposure, and other factors that alter the microbiome.

Understanding the gut–skin link opens the door to more targeted, future-friendly approaches. By supporting a healthier microbiome—through diet strategies that promote beneficial microbes, managing triggers that disrupt the gut ecosystem, and discussing evidence-based adjuncts with clinicians—people with psoriasis may be able to influence inflammation at its source rather than only treating symptoms on the skin. As research evolves, microbiome-informed therapies may complement current treatments and help personalize care for psoriatic disease.

Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test
innerbuddies gut microbiome testing

Psoriasis / psoriatic disease overlap

Psoriasis and broader psoriatic disease may be shaped by the gut microbiome through gut–skin signaling that influences immune balance. Key mechanisms involve Th17/IL-23–driven inflammation, intestinal barrier function, and microbial metabolites like short-chain fatty acids that regulate immune tolerance. Shifts toward a pro-inflammatory gut ecosystem can fuel skin plaques, fatigue, and, in some individuals, psoriatic arthritis.

Clinical patterns include the typical skin plaques and itching, nail changes, and joint symptoms; psoriasis affects about 2-3% worldwide, with roughly 20-30% of people developing psoriatic arthritis. Microbiome patterns often show reduced diversity and loss of beneficial taxa (e.g., Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale) with increased pro-inflammatory microbes (E. coli, Streptococcus). Microbial metabolites and altered bile acid signaling (FXR, TGR5) also contribute to systemic inflammatory tone that can affect skin and joints.

Testing gut microbiome can inform personalized nutrition and targeted interventions, such as fiber-focused diets and selected prebiotics/probiotics, to restore a healthier microbial balance. Tools like InnerBuddies aim to map these patterns and guide gut-directed strategies to support skin and joint health alongside standard therapies. Ongoing research seeks to identify which microbial signatures best predict flares and therapy response in psoriatic disease.

  • Depletion of major butyrate-producing taxa (Faecalibacterium prausnitzii; Roseburia spp.; Eubacterium rectale; Coprococcus spp.; Ruminococcus bromii) reduces SCFA (butyrate) production, weakening Treg-mediated tolerance and promoting Th17/IL-23–driven inflammation in psoriasis and psoriatic arthritis.
  • Expansion of pro-inflammatory taxa (Ruminococcus gnavus; Escherichia coli; Enterococcus faecalis; Streptococcus spp.; pro-inflammatory Bacteroides spp.) is linked to higher systemic inflammatory signals and more active skin and joint disease.
  • Low levels of Akkermansia muciniphila may compromise the gut mucosal barrier, increasing permeability and circulating inflammatory cues relevant to psoriatic disease.
  • Presence of beneficial taxa such as Bifidobacterium spp. and Prevotella in anti-inflammatory contexts supports gut barrier integrity and SCFA production, potentially dampening inflammatory signaling.
  • Overall gut dysbiosis tends to bias the immune system toward a Th17/IL‑23 axis, bridging gut ecology with skin and joint inflammation in psoriasis and psoriatic disease.
Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test
innerbuddies gut microbiome testing

Autoimmune disease

Psoriasis is a chronic inflammatory condition driven by an overactive immune response, and many people also experience broader psoriatic disease (including psoriatic arthritis). Increasing evidence suggests that the gut microbiome—the community of microorganisms living in the digestive tract—may influence immune balance and contribute to both skin symptoms and systemic inflammation. Research into “gut–skin” communication highlights how changes in gut microbial diversity and composition may correlate with disease activity, flare patterns, and response to certain therapies.

Several mechanisms are thought to connect the gut microbiome to psoriatic inflammation. Microbes and their byproducts can shape intestinal barrier function and immune signaling, affecting how readily inflammatory signals enter circulation. Pathways involving innate and adaptive immunity—such as Th17 responses—are particularly relevant, as they are central to psoriasis biology. Alterations in microbial metabolites (including short-chain fatty acids) may also influence regulatory immune cells, while shifts in gut-derived inflammatory cues can promote systemic inflammation that ultimately impacts the skin and joints.

Understanding these connections is opening new avenues for future treatments, such as diet-based strategies, targeted probiotics or prebiotics, and microbiome-directed therapies designed to restore a healthier microbial ecosystem and reduce inflammatory signaling. While microbiome research is still evolving, practical steps that support gut health—like emphasizing fiber-rich, minimally processed foods—may help complement overall psoriatic disease management. Ongoing studies continue to refine which microbial patterns and metabolic pathways are most important, with the goal of translating gut–skin insights into personalized, evidence-based interventions.

  • Red, scaly, well-demarcated skin plaques (common in psoriasis)
  • Itching and burning sensations on affected skin
  • Flaking and dryness of the scalp and/or skin folds
  • Joint pain, stiffness, and swelling (possible psoriatic arthritis overlap)
  • Fatigue and reduced energy related to systemic inflammation
  • Nail changes such as pitting, thickening, or separation from the nail bed
Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test
innerbuddies gut microbiome testing

Psoriasis / psoriatic disease overlap

This information is relevant for people living with psoriasis or suspected “psoriatic disease overlap,” especially those who notice that their skin symptoms don’t occur in isolation but may coincide with broader inflammatory signals—such as persistent fatigue, increased itch/burning, and recurring flares. It’s also a fit for individuals experiencing scalp or skin-fold psoriasis, where inflammation may reflect systemic immune activity rather than only local skin factors.

It may be most helpful if you have symptoms that suggest gut–skin involvement, such as a pattern of gastrointestinal discomfort, irregular bowel habits, or dietary triggers alongside worsening plaques. It’s also relevant for those with psoriatic arthritis–type symptoms (joint pain, stiffness, swelling) or nail changes (pitting, thickening, separation), because gut-derived immune signaling may contribute to the broader immune pathways implicated in both skin and joints.

Finally, this is for patients and clinicians interested in evidence-based, complementary strategies that support immune balance, including diet-first approaches (e.g., higher fiber, minimally processed foods) and microbiome-directed options such as prebiotics or targeted probiotics. If you’re exploring why some people respond differently to therapies or why flare patterns vary over time, the gut microbiome perspective can provide a practical framework for personalized lifestyle and treatment discussions aimed at reducing inflammatory signaling.

Psoriasis is common worldwide, affecting about 2–3% of the population in many epidemiologic studies. While the skin disease is the most visible component, many people with psoriasis also experience broader psoriatic disease: approximately 20–30% of individuals with psoriasis go on to develop psoriatic arthritis. This overlap matters clinically because gut–immune interactions relevant to psoriasis may also contribute to systemic inflammation and joint involvement.

In terms of symptoms, the most typical pattern includes red, well-demarcated, scaly plaques and itch/burning; scalp and flexural involvement is also frequent, and nail changes such as pitting or thickening occur in a substantial subset of patients. Nail psoriasis is reported in roughly 40–50% of people with psoriasis overall, and it can correlate with more severe disease. Fatigue is also commonly reported, reflecting systemic inflammatory burden beyond the skin lesions.

From a “gut–skin” perspective, the association between gut microbiome features and psoriatic disease activity is an active research area, but population-wide prevalence of specific microbiome signatures has not yet been established with uniform thresholds. What is clear is that psoriatic inflammation is immune-mediated (with pathways such as Th17 frequently implicated), and gut microbial dysbiosis has been linked in studies to flare patterns and disease severity. Practically, these findings help explain why many individuals experience symptoms like persistent skin flaking and joint stiffness alongside broader inflammatory symptoms, even though exact prevalence figures for microbiome changes themselves are not yet standardized.

Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test
innerbuddies gut microbiome testing

Gut Microbiome & Psoriasis: The Link in Psoriatic Disease (Overview)

Psoriasis and related psoriatic diseases are increasingly linked to the gut microbiome—both through immune effects and gut–skin signaling. Changes in microbial diversity and composition can influence intestinal barrier function and alter immune pathways that regulate inflammation, including Th17-driven responses that are central to psoriasis biology.

As gut microbes metabolize dietary components, they generate signaling molecules and metabolites (such as short-chain fatty acids) that affect regulatory immune cells and help keep inflammation in check. When the microbiome shifts toward a more inflammatory pattern, microbial byproducts and gut-derived inflammatory cues may enter circulation more easily, promoting systemic inflammation that can manifest as skin plaque flares and contribute to fatigue.

This gut–immune communication may also relate to psoriatic arthritis overlap, where joint pain, stiffness, and swelling reflect broader immune dysregulation beyond the skin. While research is still evolving, evidence supports that restoring a healthier gut ecosystem—often via fiber-rich, minimally processed foods and personalized microbiome-directed approaches like targeted prebiotics/probiotics—may help support immune balance and complement standard psoriasis management.

Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test
innerbuddies gut microbiome testing

Gut Microbiome and Psoriasis / psoriatic disease overlap

  • Th17/IL-23 immune axis modulation: Gut dysbiosis can promote Th17 differentiation and increase IL-23–driven inflammatory signaling, which is central to psoriasis and can contribute to psoriatic disease activity, including arthritis overlap.
  • Intestinal barrier dysfunction and “leaky gut” effects: Altered microbial composition and reduced beneficial metabolites can weaken tight junctions, increasing translocation of microbial products (e.g., LPS) that trigger systemic immune inflammation and may worsen skin plaques and fatigue.
  • Reduced short-chain fatty acid (SCFA) signaling: Lower microbial fermentation of dietary fiber decreases SCFAs (acetate/propionate/butyrate), which normally support regulatory T cells (Tregs) and immune tolerance; this imbalance can tilt toward inflammatory pathways.
  • Immune cell education via microbial metabolites: Bacterial metabolites (beyond SCFAs, including indoles and secondary bile acids) act as signaling molecules that influence dendritic cells, macrophages, and Tregs—shaping the inflammatory tone relevant to psoriasis.
  • Microbiome-driven antigen and pattern-recognition signaling: Increased abundance of pro-inflammatory microbial communities or their products can enhance activation of innate immune pathways (e.g., via TLRs/NLRs), amplifying inflammatory cascades that manifest in skin and joints.
  • Bile acid–microbiome–immune crosstalk: Gut bacteria transform primary to secondary bile acids, which engage host receptors (such as FXR/TGR5) that regulate inflammation and can affect psoriasis susceptibility and systemic inflammatory status.
  • Systemic inflammation through gut–skin and gut–joint signaling: Circulating cytokines and immune cells primed in the gut can home to skin and synovial tissue, reinforcing psoriatic lesions and joint inflammation in psoriatic arthritis overlap.

Psoriasis and related psoriatic diseases are increasingly understood as immune disorders influenced by the gut microbiome. A shift in microbial composition can bias immune development toward a Th17/IL-23–dominant inflammatory state, which is a key driver of psoriasis activity. When gut dysbiosis promotes Th17 differentiation and amplifies IL-23 signaling, inflammatory pathways can strengthen systemically and support flare-ups not only in the skin but also in psoriatic arthritis, where joint inflammation reflects broader immune dysregulation beyond plaques.

Gut microbes also shape inflammation through the intestinal barrier and metabolite production. When beneficial bacteria and their fermentation byproducts decline, the intestinal lining may become more permeable, allowing microbial components (for example, LPS) to cross into circulation and trigger innate immune activation. At the same time, reduced dietary fiber fermentation can lower short-chain fatty acids (SCFAs like butyrate), which normally help support regulatory T cells (Tregs) and immune tolerance. The combination of barrier dysfunction and weakened SCFA-driven “braking” of immunity can tilt the immune system toward persistent inflammatory signaling associated with psoriasis and fatigue.

Beyond SCFAs, microbiome-derived metabolites and microbial product sensing can further program immune responses. Compounds such as indoles and secondary bile acids interact with host immune cells (including dendritic cells and macrophages) and receptors that regulate inflammatory tone. Changes in bile acid profiles—driven by gut bacterial transformation of primary to secondary bile acids—can alter signaling via receptors such as FXR and TGR5, influencing systemic inflammation relevant to psoriasis risk and progression. These gut–immune communications can prime immune cells that later home to skin and synovial tissue, reinforcing lesions and joint symptoms characteristic of psoriatic disease overlap.

Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test
innerbuddies gut microbiome testing

Microbial patterns summary

In psoriatic disease with gut involvement, studies often describe a shift in microbiome composition toward reduced overall diversity and a relative loss of beneficial, gut-barrier–supporting taxa alongside an increase in microbes associated with pro-inflammatory signaling. This pattern is frequently accompanied by altered metabolic output, reflecting changes in how the community ferments fiber and handles bile acids. When microbial communities move away from a “regulatory” profile, intestinal barrier function can become less resilient and the host may experience greater exposure to microbial-associated molecules, which can prime systemic immune activation relevant to psoriasis flares and psoriatic arthritis symptoms.

A common theme is that gut dysbiosis can bias immune programming toward a Th17/IL-23–dominant inflammatory axis. Microbes and their metabolites help determine the balance between inflammatory effector cells and regulatory T cells, including via short-chain fatty acids (SCFAs) such as butyrate. When fiber-derived fermentation declines, SCFAs often drop, weakening the immune system’s tolerance mechanisms and reducing signals that normally help “brake” inflammation. In parallel, microbial products (for example, endotoxin-related components) may be more able to influence innate immune pathways if the intestinal lining becomes more permeable, contributing to ongoing inflammatory tone that can manifest in both skin and joints.

Beyond SCFAs, the psoriatic-gut pattern often involves altered metabolite signaling—especially molecules shaped by bacterial transformation of bile acids and other nutrient metabolites. Changes in secondary bile acids and other gut-derived compounds can modify signaling through immune- and metabolic-sensing pathways (such as FXR and TGR5), which can influence inflammatory cytokine production and the trafficking of immune cells to peripheral tissues. Together, these microbial metabolic shifts can create a gut–immune communication loop that sustains or amplifies the inflammation characteristic of psoriasis and the overlap with joint involvement, while also relating to systemic symptoms like fatigue.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Coprococcus spp.
  • Ruminococcus bromii
  • Akkermansia muciniphila
  • Bacteroides fragilis (notably enterotoxigenic-negative strains)
  • Bifidobacterium spp.
  • Prevotella spp. (in beneficial, anti-inflammatory contexts)


Elevated / overrepresented taxa

  • Ruminococcus gnavus
  • Escherichia coli
  • Enterococcus faecalis
  • Streptococcus spp.
  • Bacteroides spp. (including pro-inflammatory-associated strains)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis/fermentation from dietary fiber (butyrate/propionate pathways via Faecalibacterium/Roseburia/Ruminococcus spp.)
  • Intestinal barrier integrity and mucus/epithelial support pathways (e.g., mucin degradation–related metabolism affecting Akkermansia and epithelial defenses)
  • Bile acid transformation and secondary bile acid biosynthesis (microbial bile acid 7α-dehydroxylation and related steps shaping FXR/TGR5 signaling)
  • Th17/IL-23 inflammatory axis modulation by microbial metabolites (including SCFA-dependent and bile acid–dependent immune programming)
  • Microbial-associated molecular pattern (MAMP) sensing and innate immune activation (endotoxin/LPS and other permeability-linked pathways that prime systemic inflammation)
  • Proteolytic fermentation and amino-acid metabolite production (linked to rises in Ruminococcus gnavus and other pro-inflammatory fermentation products)
  • Bacterial lipopolysaccharide/enterotoxin-related functional outputs (enhanced inflammatory potential from elevated Proteobacteria/Enterococcus/Escherichia functional traits)


Diversity note

In psoriatic disease with gut involvement, the gut microbiome is often described as having reduced overall diversity and a less stable community structure. Compared with healthy controls, people may show a relative loss of taxa associated with gut-barrier support and immunoregulatory functions, alongside an increase in microbial groups that correlate with pro-inflammatory immune signaling. This shift in community balance can coincide with changes in the way the microbiome processes dietary substrates, particularly those related to fiber fermentation and bile-acid transformation.

As diversity falls and the microbial ecosystem skews away from a more “regulatory” profile, intestinal barrier resilience may decline, making it easier for microbial-associated molecules and inflammatory cues to influence the immune system. Lower production of key anti-inflammatory metabolites—especially short-chain fatty acids (SCFAs) such as butyrate, which are generated through fiber fermentation—is commonly discussed as one mechanism. With fewer of these tolerance-supporting signals, immune regulation can weaken, potentially biasing responses toward Th17/IL-23–dominant pathways that are central to psoriasis biology.

Metabolic outputs often shift together with this altered diversity, including changes in bacterial transformation of bile acids and other nutrient-derived compounds. These metabolite changes can modify immune and metabolic sensing pathways (for example, signaling through receptors involved in bile-acid and inflammatory regulation), contributing to a sustained gut–immune activation loop. In the context of psoriasis and psoriatic arthritis overlap, this dysbiotic, lower-diversity pattern may help sustain systemic inflammatory tone that can manifest as both skin flares and joint symptoms, as well as fatigue.


Get Your Gut Microbiome Test for Psoriasis Support Subscribe & Get Your Gut Microbiome Test

Why generic solutions fail

  • Issue with generic solutions

    Generic gut approaches often fail in psoriasis/psoriatic disease overlap because the gut–immune link is not driven by a single “bad bacterium” or one metabolite that can be corrected the same way in everyone. Psoriatic patients can differ widely in baseline gut diversity, intestinal permeability, bile-acid handling, dietary fiber intake, medication exposure (especially biologics, antibiotics, and NSAIDs), and gut transit time—all of which shape whether a microbiome shift actually moves immune signaling away from a Th17/IL-23–dominant inflammatory pattern. A one-size-fits-all probiotic or supplement may not address the specific ecological deficit (e.g., loss of fiber-fermenting taxa or reduced SCFA output) or the metabolic context that determines whether immune “brakes” like regulatory T-cell pathways recover.

    Many generic regimens also overlook that psoriasis-related dysbiosis is frequently accompanied by altered microbial metabolites and bile-acid transformations, not just changes in taxonomy. If someone doesn’t rebuild the substrates the microbiome needs (commonly adequate, diverse fiber and minimally processed plant intake), adding a fixed probiotic/prebiotic mix can have limited effect or even worsen tolerance by causing transient bloating or changing fermentation in the wrong direction. Likewise, if gut permeability is elevated, simply changing bacterial counts may not quickly reduce the immune exposure to microbe-associated molecules; barrier-supportive dietary patterns and individualized pacing often matter as much as the “species list.”

    Finally, generic solutions often fail because symptoms in psoriatic disease overlap (skin flares, joint pain/stiffness, fatigue) reflect systemic immune dysregulation that may not be reversible through gut modulation alone, and responses can be slow and highly individual. Without aligning the approach to a person’s diet tolerance, microbiome response capacity, and trigger profile (including fermented foods, specific fibers, and medication timing), many interventions don’t produce sustained improvements in SCFAs, bile-acid signaling (e.g., FXR/TGR5 pathways), or immune cell trafficking. The result is a mismatch between the intervention’s mechanism and the patient’s actual gut–immune drivers, leading to minimal or temporary benefits.

  • Common mistakes

    • Treating psoriasis/psoriatic-disease overlap with a one-size-fits-all probiotic or supplement, instead of targeting the individual ecological deficit (e.g., reduced fiber-fermenting taxa/SCFA output or altered bile-acid metabolism).
    • Ignoring microbiome function (metabolites like SCFAs and bile-acid–derived signaling) and focusing only on taxonomy, so interventions don’t restore the gut–immune “brakes” (regulatory/Treg balance, reduced Th17/IL-23 tone).
    • Overusing prebiotics/fiber additives without matching the person’s baseline gut tolerance and transit/permeability status, leading to bloating, intolerance, or fermentation patterns that don’t support SCFA recovery.
    • Failing to account for medication and exposure effects (especially antibiotics, biologics, NSAIDs), which can dominate microbiome signals and determine whether gut changes translate into immune improvement.
    • Not considering gut permeability/barrier resilience—assuming correcting bacterial counts alone will reduce immune exposure to microbial-associated molecules when the barrier problem may persist.
    • Missing the bile-acid axis (FXR/TGR5-related signaling) and making no dietary/metabolic adjustments to support normal bile-acid transformation, even though metabolite shifts may be a key driver of systemic inflammation.
    • Designing interventions without accounting for dietary trigger patterns (fermented foods, specific fibers, high ultra-processed intake) and medication timing, so the regimen conflicts with the patient’s flare triggers.
    • Expecting fast or universal symptom improvement, rather than recognizing that gut–immune modulation can be slow, highly individual, and may not fully reverse systemic immune dysregulation by gut changes alone.

What to do

  • General support strategies

    Psoriasis and related psoriatic conditions have growing links to the gut microbiome, largely through immune signaling that bridges the intestine and the skin. Supporting a healthier microbial ecosystem may help strengthen gut barrier function and shift immune pathways away from pro-inflammatory, Th17-dominant patterns that are central to psoriasis biology. When microbial diversity and function improve, more of the beneficial metabolites they produce—such as short-chain fatty acids—can support regulatory immune cells and promote a more controlled inflammatory tone system-wide.

    Diet is often the most practical starting point for gut support. Emphasizing fiber-rich, minimally processed foods (for example, diverse vegetables, legumes, whole grains, nuts, and seeds) helps feed beneficial microbes and increases the production of anti-inflammatory metabolites. For some people, reducing gut-irritating dietary patterns (such as high intakes of highly processed foods and added sugars) may help limit dysbiosis and reduce inflammatory signaling that can contribute to skin plaque flares, fatigue, and broader immune activation.

    Because microbiome responses can vary by individual, personalized “microbiome-directed” strategies may be considered as an adjunct to standard care. Targeted prebiotic fibers, carefully selected probiotics, and—when appropriate—evidence-informed adjustments to meal composition can be used to nudge the microbiome toward a more balanced profile. For patients with psoriatic arthritis overlap, these gut–immune improvements may also complement inflammation-focused management by supporting systemic immune regulation alongside nutrition and medical therapy.

  • Lifestyle recommendations

    • Increase fiber-rich, minimally processed foods (e.g., vegetables, legumes, whole grains, nuts) to support gut microbial diversity and beneficial metabolite production.
    • Adopt an anti-inflammatory eating pattern (e.g., Mediterranean-style) emphasizing omega-3 sources (fatty fish or chia/flax), olive oil, and plant-based meals; limit ultra-processed foods and added sugars.
    • Consider targeted prebiotic/probiotic strategies (e.g., gradually adding foods like yogurt/kefir or fermented foods; or discussing evidence-based prebiotics/probiotics with a clinician) to support a healthier gut ecosystem.
    • Identify and reduce potential dietary triggers through a structured elimination/reintroduction approach if flares correlate with specific foods (avoid unsupervised broad restrictions).
    • Maintain gut and overall health with regular physical activity and consistent sleep (support immune regulation and may reduce systemic inflammatory signaling).
    • Avoid smoking and limit alcohol, as both can worsen inflammatory pathways and may impair disease control.

  • Nutrition recommendations

    • Prioritize a high-fiber, minimally processed plant-forward diet (aim for a variety of vegetables, legumes, whole grains, nuts, and seeds) to support beneficial gut diversity and increase short-chain fatty acid production (e.g., butyrate).
    • Increase fermented and probiotic foods if tolerated (e.g., yogurt/kefir with live cultures, kimchi, sauerkraut, miso, tempeh) to promote microbiome balance and gut barrier function.
    • Use targeted prebiotic intake regularly (e.g., chicory root/inulin, garlic, onions, leeks, asparagus, oats) to feed beneficial microbes—start low if you have bloating and titrate up.
    • Choose anti-inflammatory fats and limit ultra-processed foods (focus on extra-virgin olive oil, fatty fish like salmon/sardines, and walnuts; reduce processed meats, refined sugars, and trans fats that can drive inflammatory signaling).
    • Support gut barrier health with polyphenol-rich foods (berries, citrus, pomegranate, leafy greens, green tea, extra spices like turmeric/ginger) to reduce oxidative stress and modulate immune pathways.
    • Consider an individualized trial to identify triggers (some people benefit from reducing alcohol, high-sugar intake, and/or potential dietary aggravators; if you use elimination diets, keep them time-limited and nutritionally supervised).
    • Ensure adequate omega-3 intake (via diet or clinician-guided supplementation) to complement inflammation control and may be especially relevant for skin and psoriatic arthritis overlap.

  • Supplement considerations

    For psoriasis and psoriatic disease overlap, supplement choices are often aimed at supporting a more balanced gut microbiome and strengthening gut–immune signaling that can influence inflammation. Because microbial metabolites such as short-chain fatty acids (notably butyrate, propionate, and acetate) help regulate regulatory immune pathways (including effects on T-cell balance), supplements that promote beneficial fermentation and barrier support may be particularly relevant. In practice, many people focus on fiber-type interventions (e.g., prebiotic fibers) that feed commensal microbes rather than relying solely on “live” organisms.

    Probiotic and prebiotic strategies can be considered, but response is highly individual and depends on baseline microbiome composition, diet, and medication use. Targeted probiotics (specific strains with evidence in inflammatory or immune-related contexts) and synbiotic approaches (a combination of probiotics plus complementary prebiotic substrates) may help steer the ecosystem toward a less pro-inflammatory pattern. Options such as omega-3s and curcumin are sometimes used as adjuncts for systemic inflammatory tone, which may complement gut-directed approaches—especially when there is psoriatic arthritis overlap where inflammatory signaling extends beyond the skin.

    Because gut-immune pathways interact with medication and overall tolerance, it’s important to introduce supportive supplements gradually and monitor symptoms such as bloating, stool changes, skin flares, or joint stiffness. For some people, emphasizing gut barrier and immune regulation nutrients—such as vitamin D repletion if deficient, magnesium for overall inflammatory and neuromuscular support, and targeted polyphenols from gut-friendly sources—may be more appropriate than high-dose “gut cleanses.” Working with a clinician to consider contraindications, lab markers (e.g., vitamin D), and potential interactions can help ensure that microbiome-focused supplements complement—not conflict with—standard psoriasis management.

  • Retesting / monitoring note

    For individuals with psoriasis or psoriatic-disease overlap, retesting is typically considered after a meaningful period of gut-focused dietary or probiotic/prebiotic changes—often around 8–12 weeks—because the gut microbiome can shift within days to weeks, while downstream immune signaling and clinical symptoms usually take longer to stabilize. Retesting should aim to confirm whether microbial diversity and key functional markers (e.g., gut barrier–supporting and anti-inflammatory metabolites such as short-chain fatty acids) are moving in a favorable direction, rather than relying on a single snapshot.

    When choosing when to retest, it helps to align timing with symptom cycles and current treatment context. If you’re adjusting standard psoriasis therapy, retesting should be coordinated so results are interpretable (e.g., avoid major medication changes in the immediate lead-up to testing unless your clinician is specifically evaluating interactions). For people targeting Th17-related inflammatory pathways through gut interventions, retesting may be repeated again at a longer interval (commonly 3–6 months) if the first follow-up shows partial improvement, since immune modulation and intestinal barrier recovery often require sustained microbiome remodeling.

    It’s also important that retesting uses a consistent approach to sample handling, diet, and testing conditions. Minimizing confounders such as antibiotics, bowel-prep agents, major dietary swings, and sudden changes in fiber intake improves the ability to attribute changes to the intervention. Depending on the initial results, a clinician may recommend additional retesting to refine a personalized plan—such as targeted prebiotics, probiotics, or dietary strategies—especially when psoriatic arthritis overlap is present and inflammation may fluctuate systemically.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters for psoriasis and related psoriatic disease overlap because it can reveal patterns of microbial imbalance that may be driving (or perpetuating) the immune dysfunction underlying flares. Since gut–skin signaling involves how intestinal bacteria influence immune pathways—particularly Th17-related inflammation—knowing a patient’s baseline microbial diversity and composition can help identify whether their current ecosystem is less supportive of immune tolerance and more suggestive of an inflammatory microbial profile.

    Testing is also useful because it provides clues about functional gut outputs, such as whether beneficial metabolite-producing microbes (including those associated with short-chain fatty acids like butyrate) are adequately represented. These metabolites help support the intestinal barrier and regulate inflammatory signaling; when they’re reduced, gut permeability can increase and inflammatory cues may be more likely to enter circulation, potentially contributing to systemic inflammation, fatigue, and skin plaque activity.

    Finally, microbiome data may help guide more personalized nutrition or microbiome-targeted strategies—like optimizing fiber sources or using targeted prebiotics/probiotics—rather than relying on broad, one-size-fits-all approaches. In psoriatic arthritis overlap, where inflammation extends beyond the skin to joints, aligning gut-directed interventions with the patient’s microbiome tendencies may help complement standard therapies by supporting the broader immune environment that contributes to joint pain, stiffness, and swelling.

  • How InnerBuddies helps

    The InnerBuddies test can help individuals with psoriasis and psoriatic disease overlap understand whether their gut microbiome shows patterns associated with immune-driven inflammation. Because gut–skin signaling is closely tied to pathways like Th17-mediated inflammation, microbiome shifts in diversity and specific bacterial communities may reflect an intestinal environment that is less supportive of immune tolerance—potentially correlating with flare frequency, persistence of plaque activity, and overall inflammatory load.

    By providing insight into the composition of gut microbes and related microbial signatures, InnerBuddies can also suggest whether your ecosystem may be producing fewer of the beneficial metabolites that help maintain gut barrier integrity, such as short-chain fatty acids (including butyrate). When these protective metabolites are reduced, intestinal permeability can increase and inflammatory signals may be more likely to influence the immune system systemically. That mechanism can help explain why some people experience fatigue and broader inflammatory symptoms alongside skin flares, and why gut-targeted support may complement standard psoriasis care.

    Finally, InnerBuddies can guide more personalized nutrition and microbiome-directed strategies by highlighting where your current gut ecosystem may be imbalanced. Rather than using generic dietary recommendations alone, the results can inform fiber-focused food choices and targeted prebiotic/probiotic approaches that aim to promote a more favorable microbial profile and metabolite output. For those with psoriatic arthritis overlap, this personalized gut-immune alignment may support a broader inflammatory regulation environment that complements joint-focused therapies.

Medical Evidence

  • Scientific evidence level

    2 [weak/emerging but inconsistent]

  • Clinical relevance note

    At present, microbiome research in psoriasis/psoriatic overlap is best viewed as hypothesis-generating to moderately supportive of a contributor role in disease biology, rather than as a validated clinical lever. The strongest “clinical relevance” lies in biological insight (e.g., immune/metabolite pathways consistent with Th17/IL-23 axis modulation), but translating this into reliable biomarker-driven care is not yet supported by reproducible, externally validated human data.

    For clinicians, the main practical implication is caution: gut microbiome findings in psoriasis should not be treated as diagnostic or causally explanatory without further evidence. Microbiome-targeted interventions (probiotics/prebiotics/diet) remain investigational for psoriatic disease; the evidence suggests potential but is not strong or consistent enough to guide treatment decisions. Larger, well-controlled, adequately powered prospective studies and rigorously designed RCTs with standardized microbiome methodologies and clinically meaningful endpoints are needed before microbiome testing or microbiome-targeted therapies can be considered actionable in real-world practice.

Title Journal Year Link
Microbial signatures in the gut microbiome of patients with psoriasis and psoriatic arthritis Nature Communications 2020 View →
The gut microbiome in patients with psoriatic arthritis: a case-control study Arthritis & Rheumatology 2019 View →
Targeting the gut microbiome in psoriasis: a randomized controlled trial of probiotics Journal of Dermatological Science 2018 View →
Gut microbiome in treatment-naive psoriasis patients and the effect of ustekinumab Nature Communications 2015 View →
A dysbiotic gut microbiota contributes to the development of psoriasis-like skin inflammation in mice Nature Communications 2014 View →

Frequently Asked Questions

    ¿Qué es la conexión intestino-piel en la psoriasis?
    La idea de que los microbios intestinales y sus productos influyen en respuestas inmunitarias que afectan la piel y las articulaciones.
    ¿Cómo podrían los microbios intestinales influir en la actividad de la enfermedad psoriásica?
    A través de efectos en la barrera intestinal, la señalización inmunitaria (Th17/IL‑23) y metabolitos microbianos como los SCFA.
    ¿Qué significa Th17/IL‑23 para la psoriasis?
    Th17 e IL‑23 son ejes inmunitarios a menudo implicados en la psoriasis; el microbioma intestinal puede sesgar este sistema.
    ¿La dieta puede ayudar a la psoriasis vía el microbioma?
    Una dieta rica en fibra y alimentos mínimamente procesados puede apoyar la salud intestinal y complementar la atención estándar; no sustituye el tratamiento médico.
    ¿Qué son los ácidos grasos de cadena corta (SCFA) y por qué importan?
    SCFA como el butirato respaldan células inmunitarias reguladoras y la barrera intestinal; niveles bajos pueden asociarse con mayor inflamación.
    ¿Qué es el microbiome testing y qué puede revelar?
    Las pruebas analizan patrones del microbioma y outputs metabólicos; no diagnostican la psoriasis, pero dan contexto sobre la salud intestinal.
    ¿Son fiables los resultados de pruebas de microbioma para guiar tratamiento?
    La investigación está en evolución; los resultados deben ser interpretados por un profesional de la salud.
    ¿Cómo podrían ayudar las terapias enfocadas en el microbioma?
    Buscan promover microbios o metabolitos beneficiosos para apoyar el equilibrio inmunitario; no son una cura por sí solas.
    ¿La artritis psoriásica se relaciona con cambios del microbioma intestinal?
    Existen evidencias de que señales inmunitarias intestinales pueden influir en la inflamación articular; se requieren más investigaciones.
    ¿Qué pasos prácticos puedo tomar para apoyar la salud intestinal?
    Comer alimentos ricos en fibra, preferir alimentos poco procesados, conversar con un médico sobre probióticos/prébioticos; evitar depender solo de suplementos.
    ¿Qué es InnerBuddies y cómo se relaciona con la psoriasis?
    InnerBuddies es un test que reporta patrones del microbioma y puede guiar estrategias nutricionales personalizadas; no es diagnóstico.
    ¿Qué tan comunes son la psoriasis y la artritis psoriásica?
    La psoriasis afecta a alrededor del 2–3% de la población; aproximadamente el 20–30% de las personas con psoriasis pueden desarrollar artritis psoriásica.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -